Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]

NCT00462852 is registered in ClinicalTrials.gov with Hull University Teaching Hospitals NHS Trust as lead sponsor.

NCT NCT00462852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
November 30, 2011
Enrollment
120 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, thromboembolism